234 related articles for article (PubMed ID: 31114137)
1. Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial.
Sun QH; Wang HY; Sun SD; Zhang X; Zhang H
World J Gastroenterol; 2019 May; 25(17):2110-2121. PubMed ID: 31114137
[TBL] [Abstract][Full Text] [Related]
2. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
Hsu PI; Lu CL; Wu DC; Kuo CH; Kao SS; Chang CC; Tai WC; Lai KH; Chen WC; Wang HM; Cheng JS; Tsai TJ; Chuah SK
Clin Gastroenterol Hepatol; 2015 May; 13(5):859-66.e1. PubMed ID: 25245625
[TBL] [Abstract][Full Text] [Related]
3. Management of reflux esophagitis: does the choice of proton pump inhibitor matter?
Labenz J; Armstrong D; Leodolter A; Baldycheva I
Int J Clin Pract; 2015 Jul; 69(7):796-801. PubMed ID: 25721889
[TBL] [Abstract][Full Text] [Related]
4. Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis.
Sun J; Yuan YZ; Hou XH; Zou DW; Lu B; Chen MH; Liu F; Wu KC; Zou XP; Li YQ; Zhou LY
World J Gastroenterol; 2015 Jun; 21(22):6965-73. PubMed ID: 26078574
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Evaluation of
Gan L; Wang Y; Huang S; Zheng L; Feng Q; Liu H; Liu P; Zhang K; Chen T; Fang N
Nutrients; 2024 Jan; 16(3):. PubMed ID: 38337627
[TBL] [Abstract][Full Text] [Related]
6. The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study.
Hong SJ; Park SH; Moon JS; Shin WG; Kim JG; Lee YC; Lee DH; Jang JY; Kim JJ; Lee HL; Lee SW; Hwangbo Y; Xu J; Wang B; Xue Z; Liu F; Yuan Y; Leelakusolvong S; Dy F
Gut Liver; 2016 Nov; 10(6):910-916. PubMed ID: 27282265
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double blind, controlled, multi center study of Ilaparazole in the treatment of reflux esophagitis-Phase III clinical trial.
Xue Y; Qin X; Zhou L; Lin S; Wang L; Hu H; Xia J
Contemp Clin Trials; 2018 May; 68():67-71. PubMed ID: 29540336
[TBL] [Abstract][Full Text] [Related]
8. Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole.
Liu W; Xie Y; Li Y; Zheng L; Xiao Q; Zhou X; Li Q; Yang N; Zuo K; Xu T; Lu NH; Zhang H
BMC Gastroenterol; 2022 May; 22(1):255. PubMed ID: 35596146
[TBL] [Abstract][Full Text] [Related]
9. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.
Vakil NB; Shaker R; Johnson DA; Kovacs T; Baerg RD; Hwang C; D'Amico D; Hamelin B
Aliment Pharmacol Ther; 2001 Jul; 15(7):927-35. PubMed ID: 11421866
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
[No Abstract] [Full Text] [Related]
11. A Randomized Placebo-Controlled
Sierra-Arango F; Castaño DM; Forero JD; Pérez-Riveros ED; Ardila Duarte G; Botero ML; Cárdenas A; De la Hoz-Valle J
Can J Gastroenterol Hepatol; 2019; 2019():3926051. PubMed ID: 31929980
[TBL] [Abstract][Full Text] [Related]
12. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
Moraes-Filho JP; Pedroso M; Quigley EM;
Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis.
Hsu WH; Kuo FC; Hu HM; Hsu PI; Wu DC; Kuo CH
Kaohsiung J Med Sci; 2015 May; 31(5):255-9. PubMed ID: 25910560
[TBL] [Abstract][Full Text] [Related]
14. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease.
Bayerdörffer E; Bigard MA; Weiss W; Mearin F; Rodrigo L; Dominguez Muñoz JE; Grundling H; Persson T; Svedberg LE; Keeling N; Eklund S
BMC Gastroenterol; 2016 Apr; 16():48. PubMed ID: 27080034
[TBL] [Abstract][Full Text] [Related]
15. Clinical study on sequential treatment of severe diarrhea irritable bowel syndrome with precision probiotic strains transplantation capsules, fecal microbiota transplantation capsules and live combined bacillus subtilis and enterococcus faecium capsules.
Lv L; Ruan G; Ping Y; Cheng Y; Tian Y; Xiao Z; Zhao X; Chen D; Wei Y
Front Cell Infect Microbiol; 2022; 12():1025889. PubMed ID: 36250045
[TBL] [Abstract][Full Text] [Related]
16. The innovative potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01, and Lactobacillus delbrueckii Subsp. delbrueckii LDD01 to restore the "gastric barrier effect" in patients chronically treated with PPI: a pilot study.
Del Piano M; Anderloni A; Balzarini M; Ballarè M; Carmagnola S; Montino F; Orsello M; Pagliarulo M; Tari R; Soattini L; Sforza F; Mogna L; Mogna G
J Clin Gastroenterol; 2012 Oct; 46 Suppl():S18-26. PubMed ID: 22955351
[TBL] [Abstract][Full Text] [Related]
17. GERD assessment including pH metry predicts a high response rate to PPI standard therapy.
Kandulski A; Peitz U; Mönkemüller K; Neumann H; Weigt J; Malfertheiner P
BMC Gastroenterol; 2013 Jan; 13():12. PubMed ID: 23324360
[TBL] [Abstract][Full Text] [Related]
18. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial.
van Zanten SV; Armstrong D; Chiba N; Flook N; White RJ; Chakraborty B; Gasco A
Am J Gastroenterol; 2006 Sep; 101(9):2096-106. PubMed ID: 16817845
[TBL] [Abstract][Full Text] [Related]
19. Analysis of 2-Week Data from Two Randomized, Controlled Trials Conducted in Subjects with Frequent Heartburn Treated with Esomeprazole 20 mg.
Katz PO; Le Moigne A; Pollack C
Clin Ther; 2017 May; 39(5):960-970. PubMed ID: 28431766
[TBL] [Abstract][Full Text] [Related]
20. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.
Reimer C; Søndergaard B; Hilsted L; Bytzer P
Gastroenterology; 2009 Jul; 137(1):80-7, 87.e1. PubMed ID: 19362552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
